Nuclear Localization Domains for Efficient RNA Trans-Splicing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current RNA trans-splicing techniques suffer from low efficiency due to inadequate accumulation of RNA trans-splicing molecules at the site of action within human cells, primarily because the spliceosome-mediated RNA trans-splicing requires uneven distribution of endogenous cellular enzymes throughout the cellular nucleus.

Innovation Solution

The development of compositions and methods that incorporate a nucleic acid encoding a localization domain to promote the accumulation of trans-splicing nucleic acids in the cellular nucleus, thereby enhancing the efficiency of RNA editing by increasing the localization of these molecules to the site of action.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If RNA trans-splicing molecules are administered to human cells, then therapeutic RNA editing can occur, but the efficiency is low due to inadequate accumulation at the site of action

Engineering Contradiction:
ImproveRNA trans-splicing efficiencyVSAvoidaccumulation of trans-splicing molecules at site of action
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The patent applies local quality by incorporating a nuclear localization signal (NLS) domain into the trans-splicing molecule design. This NLS domain specifically directs the molecule to accumulate in the nuclear compartment where the spliceosome machinery is located, rather than being uniformly distributed throughout the cell. This localized accumulation at the specific site of action (nucleus) directly resolves the contradiction by increasing the concentration of trans-splicing molecules where they are needed, thereby improving RNA trans-splicing efficiency.

Inventive Principle:
Principle #3Local quality

2Adaptability or versatility

If endogenous cellular enzymes are used for trans-splicing, then the process occurs naturally within the cell, but the uneven distribution of these enzymes throughout the nucleus reduces trans-splicing efficiency

Engineering Contradiction:
Improveuse of endogenous cellular enzymesVSAvoidtrans-splicing efficiency
Core Design Contradiction:
Adaptability or versatilityVSProductivity

Solution Approach 1:

The patent uses the nuclear localization signal (NLS) as an intermediary element that mediates the interaction between the trans-splicing molecule and the nuclear compartment. The NLS acts as a bridge that directs the trans-splicing molecule to the nucleus, thereby bringing it into proximity with the endogenous cellular enzymes (spliceosome) that are unevenly distributed within the nuclear space. This intermediary mechanism resolves the contradiction by enabling effective interaction despite the uneven distribution of enzymes.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS20250290067A1Localization of trans-splicing nucleic acid molecules to and within the cellular nucleus
Publication Date: 2025.09.18 TACIT THERAPEUTICS INC
  • US20250290067A1 patent drawing
  • US20250290067A1 patent drawing
  • US20250290067A1 patent drawing

AI summary

Disclosed are compositions comprising a nucleic acid encoding a localization domain. The localization domain may be configured to promote accumulation of the nucleic acid in the cellular nucleus as compared to a nucleic acid without the localization domain.